OLMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Olema Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$7.11+0.53 (+8.05%)
Close on Oct 19, 2026
- Market cap
- $742.67M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
102M of 87M shares
Institutional holders
185
26 new, 33 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
0 buys · 25 sales
Net sold $24.74M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 9,998,060 | 12.50% | 13G (passive) amendment | Feb 27, 2026 |
| Bvf Inc/Il | 8,939,731 | 9.80% | 13D (active) amendment | Oct 14, 2026 |
| Bain Capital Life Sciences Opportunities IV, L.P. | 7,473,238 | 8.15% | 13G (passive) amendment | Mar 31, 2026 |
| Senai Asefaw, M.D. | 7,429,355 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Janus Henderson Group PLC | 7,108,488 | 8.20% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 6,244,212 | 7.10% | 13G (passive) amendment | Jun 30, 2026 |
| Raymond Debbane | 4,461,949 | 5.10% | 13G (passive) | Mar 16, 2026 |
| David Kroin | 3,442,833 | 5.04% | 13G (passive) amendment | Mar 31, 2025 |
| FMR LLC | 12,075,062 | 13.80% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OLMA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 12,143,062 | 13.88% | $151.91M | +1,756,217 | 0.01% |
| Paradigm Biocapital Advisors LP | 8,670,576 | 9.91% | $108.47M | +650,000 | 2.03% |
| Jupiter Topco LLC | 7,094,413 | 8.11% | $88.80M | New | 0.04% |
| Bain Capital Life Sciences Investors, LLC | 7,085,249 | 8.10% | $88.64M | −387,989 | 5.27% |
| BlackRock, Inc. | 6,714,691 | 7.67% | $84.00M | +1,062,556 | 0.00% |
| Bvf Inc/Il | 5,295,893 | 6.05% | $66.25M | – | 1.69% |
| Siren, L.L.C. | 4,856,949 | 5.55% | $60.76M | +100,000 | 1.23% |
| State Street Corp | 4,316,058 | 4.93% | $53.99M | +378,227 | 0.00% |
| Vanguard Capital Management LLC | 3,341,217 | 3.82% | $41.80M | +257,700 | 0.00% |
| Logos Global Management LP | 3,208,875 | 3.67% | $40.14M | – | 1.73% |
| Franklin Resources Inc | 2,349,586 | 2.69% | $29.39M | +1,130,629 | 0.01% |
| Cormorant Asset Management, LP | 2,150,000 | 2.46% | $26.90M | −1,750,000 | 1.38% |
| Morgan Stanley | 1,832,269 | 2.09% | $22.92M | +616,579 | 0.00% |
| Geode Capital Management, LLC | 1,819,029 | 2.08% | $22.76M | +274,612 | 0.00% |
| Vanguard Portfolio Management LLC | 1,663,218 | 1.90% | $20.81M | +1,070,187 | 0.00% |
| Goldman Sachs Group Inc | 1,567,979 | 1.79% | $19.62M | +522,390 | 0.00% |
| Deep Track Capital, LP | 1,500,000 | 1.71% | $18.77M | New | 0.27% |
| Dimensional Fund Advisors LP | 1,416,533 | 1.62% | $17.72M | +334,099 | 0.00% |
| Lightspeed Management Company, L.L.C. | 1,355,299 | 1.55% | $16.95M | – | 0.71% |
| Kingdon Capital Management, L.L.C. | 1,200,000 | 1.37% | $15.01M | +345,000 | 1.54% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 185 | 102M | 100.0% | 26 / 74 | 60 / 33 | 22M | 15M |
| Q1 2026 | 195 | 101M | 100.0% | 46 / 73 | 51 / 50 | 26M | 11M |
| Q4 2025 | 200 | 91M | 100.0% | 87 / 55 | 39 / 13 | 37M | 14M |
| Q3 2025 | 127 | 68M | 78.1% | 21 / 41 | 37 / 15 | 6M | 8M |
| Q2 2025 | 122 | 71M | 80.7% | 18 / 56 | 28 / 29 | 11M | 6M |
| Q1 2025 | 133 | 66M | 75.3% | 25 / 48 | 42 / 47 | 7M | 13M |
| Q4 2024 | 156 | 71M | 81.5% | 37 / 53 | 39 / 9 | 21M | 8M |
| Q3 2024 | 130 | 59M | 67.2% | 19 / 47 | 43 / 17 | 11M | 10M |
| Q2 2024 | 129 | 61M | 69.9% | 29 / 53 | 33 / 25 | 13M | 9M |
| Q1 2024 | 126 | 57M | 65.3% | 30 / 40 | 35 / 17 | 11M | 6M |
| Q4 2023 | 113 | 52M | 59.9% | 33 / 43 | 21 / 17 | 10M | 5M |
| Q3 2023 | 97 | 47M | 54.1% | 18 / 35 | 31 / 8 | 14M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of OLMA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,716,953 | 3.11% | $33.99M | 0.32% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,611,290 | 2.98% | $32.67M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,046,399 | 2.34% | $25.60M | 0.03% | Jun 30, 2026 |
| Select Health Care Portfolio | 1,500,000 | 1.71% | $19.79M | 0.34% | May 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,127,200 | 1.29% | $14.87M | 0.01% | May 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 906,900 | 1.04% | $10.38M | 0.14% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 856,422 | 0.98% | $9.81M | 0.03% | Jul 31, 2026 |
| Fidelity Advisor Health Care Fund | 820,000 | 0.94% | $9.39M | 0.30% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 777,200 | 0.89% | $8.90M | 0.40% | Jul 31, 2026 |
| Franklin Small Cap Growth Fund | 693,867 | 0.79% | $7.94M | 0.32% | Jul 31, 2026 |
| PGIM Jennison Health Sciences Fund | 662,745 | 0.76% | $8.74M | 0.63% | May 29, 2026 |
| Janus Henderson Global Life Sciences Fund | 658,168 | 0.75% | $8.23M | 0.14% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 652,249 | 0.75% | $8.16M | 0.01% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 628,100 | 0.72% | $8.28M | 0.16% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 612,702 | 0.70% | $7.66M | 0.05% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sean Bohen | PRESIDENT AND CEO, Director | 237,650 | 0.27% | Feb 4, 2026 |
| Jason O'Byrne | CHIEF FINANCIAL OFFICER | – | – | Sep 2, 2026 |
| Shawnte Mitchell | CHIEF LEGAL OFFICER | 233 | 0.00% | Mar 5, 2026 |
| Sasha Lu Austin | VP of Finance and Controller | 4,488 | 0.01% | Feb 17, 2026 |
| Naseem Zojwalla | CHIEF MEDICAL OFFICER | 103,997 | 0.12% | Feb 4, 2026 |
| David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | 687,607 | 0.79% | Feb 4, 2026 |
| Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | 139,727 | 0.16% | Jan 15, 2026 |
| Cyrus Harmon | Director | 819,798 | 0.94% | Jul 27, 2026 |
| Prakash Raman | Director | – | – | Jun 23, 2026 |
| Value Fund L. P. Biotechnology | Director | 2,906,659 | 3.32% | Jun 23, 2026 |
| Partners OS Ltd. BVF | Director | 447,526 | 0.51% | Jun 23, 2026 |
| Ii Gp Llc Bvf | Director | 623,707 | 0.71% | Jun 23, 2026 |
| Value Trading Fund OS LP Biotechnology | Director | 3,684,068 | 4.21% | Jun 23, 2026 |
| Ian T. Clark | Director | 0 | – | Jun 23, 2026 |
| Cynthia M. Butitta | Director | 83,876 | 0.10% | Jun 23, 2026 |
| Andrew Rappaport | Director | 385,965 | 0.44% | Jun 23, 2026 |
| J. Scott Garland | Director | – | – | Jun 23, 2026 |
| Mark N. Lampert | Director | 2,103,522 | 2.40% | Jun 23, 2026 |
| I. Gp Llc Bvf | Director | – | – | Jun 23, 2026 |
| Inc/Il Bvf | Director | 2,103,522 | 2.40% | Jun 23, 2026 |
| Yi Larson | Director | – | – | Jun 23, 2026 |
| Gp Holdings Llc Bvf | Director | – | – | Jun 23, 2026 |
| Partners L. P/Il Bvf | Director | – | – | Jun 23, 2026 |
| Value Fund Ii Lp Biotechnology | Director | 2,523,265 | 2.88% | Jun 23, 2026 |
| Sandra Horning | Director | – | – | Jun 23, 2026 |
| G. Walmsley Graham | Director | 1,800,000 | 2.06% | Jun 23, 2026 |
| Gorjan Hrustanovic | Director | – | – | Jun 23, 2026 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | 7,500,000 | 8.57% | Jan 13, 2025 |
| Bain Capital Life Sciences Opportunities IV, L.P. | 10% owner | – | – | Jan 13, 2025 |
| Bain Capital Life Sciences Fund IV, L.P. | 10% owner | – | – | Jan 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cyrus Harmon Director | Jul 24, 2026 | Sale | −12,500 | $11.71 | $146.38K | 702,770 |
| Cyrus Harmon Director | Jul 23, 2026 | Sale | −12,500 | $11.58 | $144.75K | 715,270 |
| Shawnte Mitchell CHIEF LEGAL OFFICER | Mar 4, 2026 | Sale | −24,767 | $24.25 | $600.60K | 233 |
| Shawnte Mitchell CHIEF LEGAL OFFICER | Mar 4, 2026 | Option exercise | +25,000 | $4.37 | $109.25K | 25,000 |
| Shawnte Mitchell CHIEF LEGAL OFFICER | Mar 4, 2026 | Sale | −233 | $24.69 | $5.75K | 0 |
| Shawnte Mitchell CHIEF LEGAL OFFICER | Mar 3, 2026 | Option exercise | +15,000 | $4.37 | $65.55K | 15,000 |
| Shawnte Mitchell CHIEF LEGAL OFFICER | Mar 3, 2026 | Sale | −15,000 | $23.01 | $345.15K | 0 |
| Sasha Lu Austin VP of Finance and Controller | Feb 2, 2026 | Award | +11,700 | – | – | 16,188 |
| Cyrus Harmon Director | Jan 20, 2026 | Sale | −10,000 | $26.88 | $268.80K | 727,770 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Jan 15, 2026 | Sale | −100,000 | $28.73 | $2.87M | 139,727 |
| Cyrus Harmon Director | Jan 14, 2026 | Sale | −3,489 | $29.12 | $101.60K | 737,770 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 14, 2026 | Sale | −35,003 | $28.99 | $1.01M | 542,761 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 14, 2026 | Sale | −14,997 | $28.60 | $428.91K | 577,764 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 14, 2026 | Option exercise | +50,000 | $4.87 | $243.50K | 592,761 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Jan 13, 2026 | Sale | −3,822 | $28.01 | $107.05K | 239,727 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 13, 2026 | Sale | −200 | $28.49 | $5.70K | 542,761 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 13, 2026 | Sale | −49,800 | $27.60 | $1.37M | 542,961 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 13, 2026 | Option exercise | +50,000 | $4.87 | $243.50K | 592,761 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 12, 2026 | Sale | −10,000 | $28.34 | $283.40K | 144,846 |
| Sean Bohen President and CEO, Director | Dec 26, 2025 | Gift | −8,500 | – | – | 237,650 |
| Naseem Zojwalla Chief Medical Officer | Dec 23, 2025 | Option exercise | +50,000 | $7.02 | $351.00K | 103,997 |
| Naseem Zojwalla Chief Medical Officer | Dec 23, 2025 | Sale | −99,509 | $27.66 | $2.75M | 4,488 |
| Cyrus Harmon Director | Dec 22, 2025 | Sale | −2,881 | $28.53 | $82.19K | 741,259 |
| Naseem Zojwalla Chief Medical Officer | Dec 22, 2025 | Option exercise | +7,182 | $7.02 | $50.42K | 153,997 |
| Naseem Zojwalla Chief Medical Officer | Dec 22, 2025 | Option exercise | +42,818 | $15.25 | $652.97K | 146,815 |
| Naseem Zojwalla Chief Medical Officer | Dec 22, 2025 | Sale | −100,000 | $28.04 | $2.80M | 53,997 |
| Ian T. Clark Director | Dec 19, 2025 | Sale | −41,840 | $30.48 | $1.28M | 0 |
| Ian T. Clark Director | Dec 19, 2025 | Sale | −193,056 | $29.71 | $5.74M | 41,840 |
| Ian T. Clark Director | Dec 19, 2025 | Sale | −29,904 | $28.83 | $862.13K | 234,896 |
| Ian T. Clark Director | Dec 19, 2025 | Option exercise | +12,070 | $4.08 | $49.25K | 264,800 |
| Ian T. Clark Director | Dec 19, 2025 | Option exercise | +21,520 | $7.84 | $168.72K | 252,730 |
| Ian T. Clark Director | Dec 19, 2025 | Option exercise | +21,520 | $3.61 | $77.69K | 231,210 |
| Ian T. Clark Director | Dec 19, 2025 | Option exercise | +209,690 | $4.41 | $924.73K | 209,690 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Dec 19, 2025 | Sale | −1,225 | $28.08 | $34.40K | 601,656 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Dec 19, 2025 | Sale | −43,729 | $30.40 | $1.33M | 557,927 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Dec 19, 2025 | Sale | −6,046 | $31.39 | $189.78K | 551,881 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Dec 19, 2025 | Gift | −9,000 | – | – | 542,881 |
| Naseem Zojwalla Chief Medical Officer | Dec 19, 2025 | Sale | −12,921 | $28.93 | $373.80K | 103,997 |
| Naseem Zojwalla Chief Medical Officer | Dec 19, 2025 | Sale | −57,079 | $28.03 | $1.60M | 116,918 |
| Naseem Zojwalla Chief Medical Officer | Dec 19, 2025 | Option exercise | +40,000 | $15.25 | $610.00K | 173,997 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Dec 8, 2025 | Gift | −75,000 | – | – | 243,549 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Nov 26, 2025 | Gift | −225,000 | – | – | 318,549 |
| Andrew Rappaport Director | Nov 25, 2025 | Gift | −35,868 | – | – | 0 |
| Andrew Rappaport Director | Nov 21, 2025 | Option exercise | +35,868 | $0.39 | $13.99K | 35,868 |
| Cyrus Harmon Director | Sep 18, 2025 | Sale | −3,086 | $8.32 | $25.68K | 117,028 |
| Cyrus Harmon Director | Sep 18, 2025 | Sale | −10,000 | $8.33 | $83.30K | 744,140 |
| Cyrus Harmon Director | Sep 16, 2025 | Sale | −1,914 | $8.08 | $15.47K | 120,114 |
| Cyrus Harmon Director | Sep 16, 2025 | Sale | −10,000 | $8.04 | $80.40K | 754,140 |
| Partners OS Ltd. BVF Director | Jan 10, 2025 | Returned to company | −22,740 | – | – | 347,970 |
| Partners OS Ltd. BVF Director | Jan 10, 2025 | Returned to company | −235,450 | – | – | 2,655,977 |
| Partners OS Ltd. BVF Director | Jan 10, 2025 | Returned to company | −161,810 | – | – | 2,003,966 |
| Bain Capital Life Sciences Investors, LLC 10% owner | Jan 10, 2025 | Other | −3,500,000 | – | – | 4,300,000 |
| Bain Capital Life Sciences Investors, LLC 10% owner | Jan 8, 2025 | Buy | +300,000 | $5.76 | $1.73M | 7,800,000 |
| G. Walmsley Graham Director | Dec 17, 2024 | Sale | −700,761 | $6.75 | $4.73M | 0 |
| G. Walmsley Graham Director | Dec 17, 2024 | Buy | −700,761 | $6.75 | $4.73M | 1,408,875 |
| Naseem Zojwalla CHIEF MEDICAL OFFICER | Dec 16, 2024 | Option exercise | +14,000 | $4.87 | $68.18K | 129,509 |
| G. Walmsley Graham Director | Dec 13, 2024 | Buy | +700,761 | $6.75 | $4.73M | 700,761 |
| G. Walmsley Graham Director | Dec 13, 2024 | Sale | −700,761 | $6.75 | $4.73M | 0 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Dec 11, 2024 | Sale | −406 | $9.39 | $3.81K | 543,549 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Dec 11, 2024 | Sale | −17,950 | $8.66 | $155.45K | 543,955 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Cyrus Harmon Director | Jul 24, 2026 | 12,500 | $146.42K | Jul 24, 2026 | Founders Shares |
| Cyrus Harmon Director | Jul 23, 2026 | 12,500 | $144.74K | Jul 23, 2026 | Founders Shares |
| Shane William Charles Kovacs Former Officer | Mar 16, 2026 | 100,000 | $1.61M | Mar 16, 2026 | Option Granted - 02/01/2023 |
| Shane William Charles Kovacs Former Officer | Mar 16, 2026 | 4,166 | $69.18K | Mar 16, 2026 | Option Granted - 02/01/2023 |
| Shane William Charles Kovacs Former Officer | Mar 11, 2026 | 50,000 | $796.80K | Mar 11, 2026 | Option Granted - 02/01/2023 |
| Shane William Charles Kovacs Former Officer | Mar 10, 2026 | 53,206 | $904.57K | Mar 10, 2026 | Restricted Stock Vesting |
| Shane William Charles Kovacs Former Officer | Mar 9, 2026 | 241,999 | $3.25M | Mar 9, 2026 | Option Granted 02/01/2022 |
| Shane William Charles Kovacs Former Officer | Mar 4, 2026 | 20,000 | $488.65K | Mar 4, 2026 | Restricted Stock Vesting |
| Shawnte Mitchell Officer | Mar 4, 2026 | 25,000 | $598.50K | Mar 4, 2026 | Option Granted - 02/28/2025 |
| Shawnte Mitchell Officer | Mar 3, 2026 | 15,000 | $345.15K | Mar 3, 2026 | Options Granted - 02/28/2025 |
| Shane William Charles Kovacs Former Officer | Feb 27, 2026 | 6,521 | $163.03K | Feb 27, 2026 | Restricted Stock Vesting |
| Shane William Charles Kovacs Former Officer | Feb 24, 2026 | 20,000 | $500.00K | Feb 24, 2026 | Restricted Stock Vesting |
| Shane William Charles Kovacs Former Officer | Feb 23, 2026 | 10,000 | $243.00K | Feb 23, 2026 | Restricted Stock Vesting |
| Shane William Charles Kovacs Former Officer | Feb 23, 2026 | 20,000 | $480.01K | Feb 23, 2026 | Restricted Stock Vesting |
| Shane William Charles Kovacs Former Officer | Feb 12, 2026 | 10,000 | $238.50K | Feb 12, 2026 | Restricted Stock Vesting |